TG Therapeutics, Inc. (TGTX)

Market Cap	5.12B -17.3%
Revenue (ttm)	616.29M +87.3%
Net Income	447.18M +1,812.4%
EPS	2.77 +1,746.7%
Shares Out	147.68M
PE Ratio	12.55
Forward PE	25.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	443,142
Open	34.56
Previous Close	34.60
Day's Range	34.43 - 34.94
52-Week Range	25.28 - 46.48
Beta	1.76
Analysts	Strong Buy
Price Target	49.80 (+43.52%)
Earnings Date	May 4, 2026

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 399
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Analyst Summary

According to 5 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price target is $49.8, which is an increase of 43.52% from the latest price.

Price Target

$49.8

(43.52% upside)

Analyst Consensus: Strong Buy